[1] Z.X. Zhang, and G.C. Roman, Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 12 (1993) 195-208.
[2] Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Neurology 17 (2018) 939-953.
[3] K. Jomova, D. Vondrakova, M. Lawson, and M. Valko, Metals, oxidative stress and neurodegenerative disorders. Molecular and cellular biochemistry 345 (2010) 91-104.
[4] C. Zhou, Y. Huang, and S. Przedborski, Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Annals of the New York Academy of Sciences 1147 (2008) 93-104.
[5] W.H. Church, and V.L. Ward, Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain research bulletin 33 (1994) 419-25.
[6] W. Duan, B. Ladenheim, R.G. Cutler, Kruman, II, J.L. Cadet, and M.P. Mattson, Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. Journal of neurochemistry 80 (2002) 101-10.
[7] T. Mikami, and M. Sorimachi, Uric acid contributes greatly to hepatic antioxidant capacity besides protein. Physiological research 66 (2017) 1001-1007.
[8] P. Ungprasert, N. Srivali, and C. Thongprayoon, Gout is not associated with a lower risk of Parkinson's disease: A systematic review and meta-analysis. Parkinsonism & related disorders 21 (2015) 1238-42.
[9] J. Pakpoor, O.O. Seminog, S.V. Ramagopalan, and M.J. Goldacre, Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies. BMC neurology 15 (2015) 16.
[10] M. De Vera, M.M. Rahman, J. Rankin, J. Kopec, X. Gao, and H. Choi, Gout and the risk of Parkinson's disease: a cohort study. Arthritis and rheumatism 59 (2008) 1549-54.
[11] A. Alonso, L.A. Rodriguez, G. Logroscino, and M.A. Hernan, Gout and risk of Parkinson disease: a prospective study. Neurology 69 (2007) 1696-700.
[12] S.-W. Lai, C.-H. Lin, C.-L. Lin, and K.-F. Liao, Gout and Parkinson's disease in older people: an observation in Taiwan. International Journal of Gerontology 8 (2014) 166-167.
[13] E. Schernhammer, J. Qiu, L. Wermuth, C.F. Lassen, S. Friis, and B. Ritz, Gout and the risk of Parkinson's disease in Denmark. European journal of epidemiology 28 (2013) 359-60.
[14] S.K. Van Den Eeden, C.M. Tanner, A.L. Bernstein, R.D. Fross, A. Leimpeter, D.A. Bloch, and L.M. Nelson, Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. American journal of epidemiology 157 (2003) 1015-22.
[15] N. Dahodwala, A. Siderowf, M. Xie, E. Noll, M. Stern, and D.S. Mandell, Racial differences in the diagnosis of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society 24 (2009) 1200-5.
[16] C.Y. Wu, Y.J. Chen, H.J. Ho, Y.C. Hsu, K.N. Kuo, M.S. Wu, and J.T. Lin, Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA : the journal of the American Medical Association 308 (2012) 1906-14.
[17] N.H.I.R. Database., National Health Research Institutes.
[18] P.H. Bednarek, M.D. Creinin, M.F. Reeves, C. Cwiak, E. Espey, J.T. Jensen, and I.U.D.R.S.T.G. Post-Aspiration, Immediate versus delayed IUD insertion after uterine aspiration. The New England journal of medicine 364 (2011) 2208-17.
[19] E. Karis, D.B. Crittenden, and M.H. Pillinger, Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. Southern medical journal 107 (2014) 235-41.
[20] A.M. Abeles, Hyperuricemia, gout, and cardiovascular disease: an update. Current rheumatology reports 17 (2015) 13.
[21] L.B. Kienhorst, E. van Lochem, W. Kievit, N. Dalbeth, M.E. Merriman, A. Phipps-Green, A. Loof, W. van Heerde, S. Vermeulen, L.K. Stamp, E. van Koolwijk, J. de Graaf, D. Holzinger, J. Roth, H.J. Janssens, T.R. Merriman, J.C. Broen, M. Janssen, and T.R. Radstake, Gout Is a Chronic Inflammatory Disease in Which High Levels of Interleukin-8 (CXCL8), Myeloid-Related Protein 8/Myeloid-Related Protein 14 Complex, and an Altered Proteome Are Associated With Diabetes Mellitus and Cardiovascular Disease. Arthritis & rheumatology (Hoboken, N.J.) 67 (2015) 3303-13.
[22] P. Zhang, and B. Tian, Metabolic syndrome: an important risk factor for Parkinson's disease. Oxidative medicine and cellular longevity 2014 (2014) 729194.
[23] G.E. Nam, S.M. Kim, K. Han, N.H. Kim, H.S. Chung, J.W. Kim, B. Han, S.J. Cho, J.H. Yu, Y.G. Park, and K.M. Choi, Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study. PLoS medicine 15 (2018) e1002640.
[24] G. Hu, P. Jousilahti, S. Bidel, R. Antikainen, and J. Tuomilehto, Type 2 diabetes and the risk of Parkinson's disease. Diabetes care 30 (2007) 842-7.
[25] A.K. So, and F. Martinon, Inflammation in gout: mechanisms and therapeutic targets. Nature reviews. Rheumatology 13 (2017) 639-647.
[26] E.C. Hirsch, and S. Hunot, Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet neurology 8 (2009) 382-97.
[27] P.S. Whitton, Inflammation as a causative factor in the aetiology of Parkinson's disease. British journal of pharmacology 150 (2007) 963-76.
[28] M.A. Hernan, G. Logroscino, and L.A. Garcia Rodriguez, Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 (2006) 1097-9.
[29] J.J. Gagne, and M.C. Power, Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74 (2010) 995-1002.
[30] L.M. de Lau, P.J. Koudstaal, A. Hofman, and M.M. Breteler, Serum cholesterol levels and the risk of Parkinson's disease. American journal of epidemiology 164 (2006) 998-1002.
[31] A. Elbaz, and F. Moisan, Update in the epidemiology of Parkinson's disease. Current opinion in neurology 21 (2008) 454-60.
[32] J. Costa, N. Lunet, C. Santos, J. Santos, and A. Vaz-Carneiro, Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. Journal of Alzheimer's disease : JAD 20 Suppl 1 (2010) S221-38.
[33] C.M. Tanner, F. Kamel, G.W. Ross, J.A. Hoppin, S.M. Goldman, M. Korell, C. Marras, G.S. Bhudhikanok, M. Kasten, A.R. Chade, K. Comyns, M.B. Richards, C. Meng, B. Priestley, H.H. Fernandez, F. Cambi, D.M. Umbach, A. Blair, D.P. Sandler, and J.W. Langston, Rotenone, paraquat, and Parkinson's disease. Environmental health perspectives 119 (2011) 866-72.
[34] L.M. de Lau, and M.M. Breteler, Epidemiology of Parkinson's disease. Lancet neurology 5 (2006) 525-35.